The cross-reactivity of substrates, modulators with other enzymes significantly reduces/prevents our ability to design such highly specific, that is, "one warhead-one target", modulators. On the other hand, the potential "impasse" fuels repurposing of already developed drugs. Additionally, expanding our understanding that there will be "off-target" effects for enzymes of different evolutionary kingdoms propels the development of covalent reversible drugs. In this review/perspective, we examine these challenges and opportunities based on covalent drugs used/developed for targeting bacterial and mammalian enzymes, and our evolving understanding of the blurred difference between these enzymes in these "vastly" separated organisms by biological evolution.
Building similarity graph...
Analyzing shared references across papers
Loading...
Monika I. Konaklieva
Balbina J. Plotkin
BioMed Research International
American University
Midwestern University
Building similarity graph...
Analyzing shared references across papers
Loading...
Konaklieva et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69c37be2b34aaaeb1a67ec82 — DOI: https://doi.org/10.1155/bmri/3429646